Quick Facts

• Support for minor surface wounds and abrasions.
• Aids in protection from external environmental factors.
• Used on cattle, horses, dogs, cats, swine, and sheep.

---

What Alospray treats: Main Uses and Benefits

Alospray (also known as AluSpray, a veterinary product) is used to support the management of wounds on a range of species, including horses, cattle, swine, sheep, dogs, and cats. Its primary application is to provide a physical coating over minor cuts and surface abrasions.

This application may assist in creating a barrier against contamination from external environmental irritants. The spray helps to maintain a hygienic environment for the wound area while supporting the natural healing process by allowing the tissue to breathe. The film contributes to protecting the area from dirt and debris. It is indicated for the protection and healing of wounds in these target species. The product is intended for superficial wounds and is not recommended for deep, infected, or complex lesions.

Regulatory References

1. Health Products Regulatory Authority Summary of Product Characteristics

Official Population Eligibility Rules

Alospray (AluSpray) is a veterinary medicinal product, and its eligibility is strictly defined by regulatory authorization for use in specific animal species. The product is authorized for use in seven primary populations: Cattle, Horses, Swine, Poultry, Sheep, Dogs, and Cats.

Contraindications and Restrictions

Use of Alospray is contraindicated (absolutely prohibited) in any animal with a known history of hypersensitivity or allergy to the active substance, Aluminum Powder, or any of the product's excipients. Furthermore, the official regulatory documents specify that the product must not be used in animals suffering from severe renal impairment (kidney disease).

Special Population Status

Regarding physiological states, the product can be used in target species during pregnancy. However, use is explicitly not authorised for treating teat injuries in lactating animals that are producing milk intended for human consumption. No specific age-related restrictions, such as minimum age thresholds, are formally documented, with eligibility defined by the approved species category.

Interactions with other medicines and products

This section describes interactions officially documented in government regulatory sources for the Chlorhexidine Gluconate component of Alospray. The interaction profile is primarily defined by the drug's localized site of action and minimal systemic absorption.

Category	Interacting Substance/Product	Official Interaction Pattern
Local Incompatibility	Anionic Agents	Incompatible with anionic agents, such as those often found in conventional dentifrices (toothpastes) [Source 2.5].
Timing-Based Constraint	Food, Beverages, Water, Other Mouthwashes	Immediate rinsing, eating, or drinking is documented to decrease the residual local effectiveness of the medication [Source 1.6, 2.2].
Systemic Exposure Change	Oral Digoxin, Oral Estrogens	Oral chlorhexidine may potentially alter the systemic level or effect of drugs like digoxin and certain estrogens by acting on the intestinal flora [Source 1.1].

Regulatory documents mandate that the drug is prohibited for use by individuals with a known hypersensitivity to chlorhexidine gluconate or any of its components [Source 1.9]. Because of the incompatibility with anionic agents, products containing these substances must be used either before the oral rinse with a water rinse in between, or at a different time of day [Source 2.5]. Timing restrictions stipulate that eating, drinking, or rinsing must be avoided immediately following use to maintain the active concentration at the site of action [Source 1.6, 2.2]. The potential interaction with oral digoxin is formally described as potentially increasing its level or effect, while the potential interaction with oral estrogens is described as potentially decreasing their level or effect [Source 1.1].

Cationic Action and Immediate Microbial Cell Lysis

The mechanism of Alospray is initiated by the cationic charge of its active molecule, Chlorhexidine Gluconate. This positive charge is chemically attracted to the anionic molecules present on microbial cell surfaces, specifically the cell wall and cytoplasmic membrane. This strong, non-covalent binding destabilizes the cell structure, causing it to become permeable. At effective concentrations, this process culminates in the irreversible coagulation of essential intracellular macromolecules, leading to rapid cell lysis and physical destruction of the microorganisms on the application surface.

---

Tissue Substantivity and Sustained Pathogen Suppression

A primary mechanistic characteristic is substantivity, which refers to the molecule’s ability to bind to the anionic proteins and mucins present on the application surface. This creates a temporary, local reservoir of the active agent. This sustained-release pathway ensures that the molecule is gradually released over several hours, resulting in a sustained concentration of the active agent on the treated site. The mechanism is, however, constrained by chemical susceptibility, as anionic compounds (like soap) or organic matter can bind to the agent and reduce its antimicrobial function.

Alospray is strictly intended for topical administration, delivered as a cutaneous spray, powder formulation. The usage protocol involves a preparatory phase for the affected area. Before the product is administered, the wound or surface must be meticulously cleaned, disinfected, and sutured if necessary to establish optimal conditions for subsequent application.

---

The established dosing regimen for the product is based on achieving complete coverage of the injury rather than volumetric measurement. Administration requires the delivery of a superficial application that creates a fine, continuous coating of the powder over the entire wound surface. This action is repeated once or twice daily, with the goal of maintaining the protective layer until the affected area is fully healed, which defines the duration of the use.

---

To ensure correct administration, specific steps must be followed: the container must be shaken well immediately prior to application, and the product must be used unaltered from its original state. Furthermore, there are constraints concerning the recipient and environment. The product is not to be used in animals suffering from severe renal impairment, and it is explicitly restricted from use on teat injuries in lactating animals producing milk for human consumption. Application should also take place outdoors or in a well-ventilated area.

Alospray: Recent Clinical Evidence

The clinical profile of Alospray (Olopatadine Hydrochloride Nasal Spray) has been primarily established through randomized, controlled trials focusing on its use in allergic rhinitis.

Efficacy Data

Studies have investigated the efficacy of Alospray, specifically the 0.6% formulation, in managing the symptoms associated with seasonal allergic rhinitis (SAR) in both adolescents and adults. A key measure in these trials is the Total Nasal Symptom Score (TNSS), which aggregates scores for symptoms such as nasal congestion, sneezing, itchy nose, and runny nose.

• Symptom Reduction: Data from a Phase III, multicenter, double-blind study indicated that participants receiving Alospray experienced a statistically significant reduction in TNSS compared to those receiving a placebo. This benefit was observed across the major nasal symptoms evaluated.
• Onset of Action: Clinical research utilizing an environmental exposure chamber (EEC) model suggested that a measurable effect on symptoms may occur relatively quickly following administration, with effects observed as early as 30 minutes in some reports.
• Quality of Life: Conference abstracts and clinical reports have indicated that the use of intranasal olopatadine may be associated with improvement in patient-reported quality of life metrics, including daily activities and practical problems, compared to placebo in children with SAR.

Safety and Tolerability

The safety profile of Alospray was assessed throughout the clinical development program. In studies, the drug was generally reported to be well-tolerated. The most commonly reported adverse events included: bitter taste, headache, and epistaxis (nosebleed), which were typically mild in severity.

Comparative trials have also been conducted to evaluate Alospray against other established treatments for allergic rhinitis, with some studies suggesting comparable efficacy and highlighting potential differences in patient satisfaction regarding sensory attributes.

Common questions about Alospray (FAQ)

Q: Does Alospray start working right away, or does it take time?

A: Regulatory information indicates that the active molecule works through a mechanism that causes rapid disruption of microorganisms upon contact. Due to its unique properties, the active ingredient also binds to the application surface, which helps sustain its presence and germicidal effect for several hours after the initial use.

---

Q: What are the restrictions on who can use Alospray?

A: Official eligibility rules state that the use of this veterinary product is authorized for specific animal species (Cattle, Horses, Swine, Poultry, Sheep, Dogs, and Cats). The product is formally contraindicated (prohibited) in animals that have a known hypersensitivity to any of its components or those suffering from severe renal impairment (kidney disease).

---

Q: What other common medications can interact with Alospray?

A: In official documents, potential interactions are described with anionic agents, which are cleaning ingredients often found in certain soaps or detergents. Based on the active ingredient's profile, potential for altering the systemic level or effect of oral digoxin or oral estrogens is also described.

---

Q: Can Alospray be used by people with liver or kidney issues?

A: Official product information for this veterinary spray specifies that its use is contraindicated in target animals with severe renal impairment (kidney disease). The regulatory label does not provide specific information or restrictions regarding liver function.

---

Q: Does Alospray affect blood pressure or heart rate?

A: The official safety profile for the active ingredient does not list effects on blood pressure or heart rate as common occurrences. However, extremely rare, serious hypersensitivity reactions (anaphylaxis) have been reported, which may involve cardiovascular changes.

---

Q: What is the meaning of the warning about vision changes with Alospray?

A: The regulatory warning emphasizes avoiding contact with the eyes due to the potential for severe ocular injury. Contact with the eyes and middle ear must be strictly avoided as specified in the safety documentation.

---

Q: Is Alospray considered a high-risk medication?

A: Regulatory documents outline the safety profile by noting common local issues (such as staining or irritation) and the rare, but serious, risk of a systemic immune response, such as anaphylaxis. It also carries specific contraindications, such as for animals with severe kidney impairment.

---

Q: Are there any foods or drinks that should be avoided when using Alospray?

A: Official guidance does not describe specific foods or drinks that must be avoided entirely. However, for formulations applied to mucosal surfaces, immediate rinsing, eating, or drinking after use may reduce the localized effect of the active ingredient.

---

Q: Can someone who is pregnant or breastfeeding use Alospray?

A: Official eligibility rules state that the product is authorized for use in target species during pregnancy. However, its use is explicitly not authorised for treating teat injuries in lactating animals that are producing milk intended for human consumption.

---

Q: Do older adults use Alospray differently than younger people?

A: The official population eligibility rules for this veterinary product state that there are no formally documented specific age-related restrictions or differences in use required for older target species compared to younger target species.

---

Q: What temperature should Alospray be stored at?

A: The product should be stored according to manufacturer's instructions, typically at controlled room temperature, such as 15 C - 30 C (59 F - 86 F). Protection from freezing is also specified to help maintain product potency.

---

Q: Does the propellant used in Alospray pose an environmental risk?

A: Official risk assessments for the active ingredient (Chlorhexidine) indicate that it is classified as potentially toxic to aquatic life and may have long-lasting environmental effects. Disposal guidance emphasizes avoiding the release of the active ingredient into the environment.

---

Q: How is Alospray disposal managed?

A: Unused or expired product should be disposed of in accordance with local drug take-back programs or regulations. The label advises against flushing medications down the toilet or pouring them down a sink unless the official documents explicitly instruct this method.

Storage & Disposal Map: How to Store and Dispose of Alospray — official regulatory information

Storage & disposal scope

Requirement	Official Classification Wording
Labeled storage temperature requirements:	Store according to the manufacturer's instructions to ensure the product maintains its potency and effectiveness until the expiration date.
Light/moisture protection requirements:	Keep the product in its original container and protect it from excessive heat, light, and humidity, unless otherwise specified on the label.
Handling requirements:	Protect from freezing. Do not use past the expiration date listed on the packaging.
Disposal instructions (as documented in government sources):	Dispose of unused or expired product according to local drug take-back programs or regulations. Do not flush medications down the toilet or pour them down a sink unless the label explicitly instructs to do so.
Child-protection storage requirements (if stated):	Keep this and all medicines out of the sight and reach of children.

Connection to the overall storage/disposal profile:

Regulatory agencies require that Alospray's labeling clearly define its storage conditions, which typically include a specific temperature range, protection from light and moisture, and handling rules like preventing freezing. The product must be stored securely away from children. Final disposal must adhere to official guidelines, such as using authorized medicine take-back programs, to safely manage the product after its use or expiration.